Closantel
Based on 11 publication(s) in Google Scholar
Closantel is a halogenated salicylanilide with a potent anti-parasitic activity. Closantel is a potent and highly specific Onchocerca volvulus chitinase (OvCHT1) inhibitor with an IC50 of 1.6 μM and a Ki of 468 nM. Closantel inhibits the O. volvulus L3 to L4 molt of developing.
For research use only. We do not sell to patients.
- Purity: 98.65%
- CAS No.: 57808-65-8
- Formula: C22H14Cl2I2N2O2
- Molecular Weight:663.07
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antiparasitic Compound library
HY-L082
-
Human Metabolite Library
HY-L123
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Closantel
More- Acta Pharm Sin B. 2025 Mar;15(3):1535-1551. [Abstract]
- Autophagy. 2026 Mar 5. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- J Mol Cell Biol. 2023 Aug 3;15(3):mjad017. [Abstract]
- Microbiologyopen. 2025 Oct;14(5):e70062. [Abstract]
- Cancers. 2020 Mar 2;12(3):575. [Abstract]
- J Biol Chem. 2022 Oct;298(10):102417. [Abstract]
- Drug Repurposing. 2026 Jan 30.
- bioRxiv. 2025 March 01.
- Università Vita-Salute San Raffaele. 2022 Apr 08. 34.
- L’UNIVERSITE GRENOBLE ALPES. 2021 Apr 13.
Customer Validation & Images
-
RT-PCR
-
Cell Imaging/Staining
-
Histological Imaging/Staining
All Parasite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | CC50 |
75 μM
Compound: Closantel
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
|
[PMID: 30392371] |
| HEK293 | IC50 |
3 μM
Compound: Closantel
|
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
|
[PMID: 28230985] |
Closantel, a known anthelmintic drug, is highly specific forfilarial family chitinases compared to those fromprotozoans and the human chitinase, human chitotriosidase[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 57808-65-8
-
Appearance Solid
-
Molecular Weight 663.07
-
Formula C22H14Cl2I2N2O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC(Cl)=C(C(C2=CC=C(Cl)C=C2)C#N)C=C1C)C3=CC(I)=CC(I)=C3O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
2025 Mar;15(3):1535-1551. PMID: 40370558
Closantel purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Mar;15(3):1535-1551. [Abstract]
HEK293T cells were pretreated with 20 μmol/L Closantel for 1 h and then infected with indicated MOI HSV-1 for 24 h. HSV-1 RNA replicates were detected by qPCR.
-
Autophagy
2026 Mar 5. PMID: 41787744 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
J Mol Cell Biol
2023 Aug 3;15(3):mjad017. PMID: 36921991 -
Microbiologyopen
2025 Oct;14(5):e70062. PMID: 40926309 -
Cancers
2020 Mar 2;12(3):575. PMID: 32131390
Closantel purchased from MedChemExpress. Usage Cited in: Cancers. 2020 Mar 2;12(3):575. [Abstract]
Representative images of embryos before and after treated with DMSO (vehicle), PTK787, WNK463 or Closantel (0.15 μM).
Closantel purchased from MedChemExpress. Usage Cited in: Cancers. 2020 Mar 2;12(3):575. [Abstract]
Representative H&E-stained sections of intestinal tract of RPIA transgenic fish treated with Closantel (1.5 μM).
-
J Biol Chem
α-Crystallin chaperone mimetic drugs inhibit lens γ-crystallin aggregation: Potential role for cataract prevention. [Abstract]2022 Oct;298(10):102417. PMID: 36037967 -
-
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (150.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Amanda L Garner, et al. Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus. J Med Chem. 2011 Jun 9;54(11):3963-72. [Content Brief]
[2]. Amanda L Garner, et al. Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus. J Med Chem. 2011 Jun 9;54(11):3963-72. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5081 mL | 7.5407 mL | 15.0814 mL | 37.7034 mL |
| 5 mM | 0.3016 mL | 1.5081 mL | 3.0163 mL | 7.5407 mL | |
| 10 mM | 0.1508 mL | 0.7541 mL | 1.5081 mL | 3.7703 mL | |
| 15 mM | 0.1005 mL | 0.5027 mL | 1.0054 mL | 2.5136 mL | |
| 20 mM | 0.0754 mL | 0.3770 mL | 0.7541 mL | 1.8852 mL | |
| 25 mM | 0.0603 mL | 0.3016 mL | 0.6033 mL | 1.5081 mL | |
| 30 mM | 0.0503 mL | 0.2514 mL | 0.5027 mL | 1.2568 mL | |
| 40 mM | 0.0377 mL | 0.1885 mL | 0.3770 mL | 0.9426 mL | |
| 50 mM | 0.0302 mL | 0.1508 mL | 0.3016 mL | 0.7541 mL | |
| 60 mM | 0.0251 mL | 0.1257 mL | 0.2514 mL | 0.6284 mL | |
| 80 mM | 0.0189 mL | 0.0943 mL | 0.1885 mL | 0.4713 mL | |
| 100 mM | 0.0151 mL | 0.0754 mL | 0.1508 mL | 0.3770 mL |
Closantel Related Classifications
HY-17596 Related Classifications
Powered by Bioz